Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
Research and Development
$424 Mil (TTM As of Sep. 2016)

This is the expense the company spent on research and development. Valeant Pharmaceuticals International Inc's research and development for the three months ended in Sep. 2016 was $101 Mil. Its research and development for the trailing twelve months (TTM) ended in Sep. 2016 was $424 Mil.


Definition

This is the expense the company spent on research and development.

Valeant Pharmaceuticals International Inc Research & Development for the trailing twelve months (TTM) ended in Sep. 2016 was 95.9 (Dec. 2015 ) + 103.1 (Mar. 2016 ) + 124.3 (Jun. 2016 ) + 100.8 (Sep. 2016 ) = $424 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 95118931071586679157246334

Valeant Pharmaceuticals International Inc Quarterly Data

Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16
Research & Development 675959568110296103124101
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK